Uni Eropa - Jerman - EMA (European Medicines Agency)

lipomed gmbh - thalidomid - multiples myelom - immunsuppressiva - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - idecabtagenum vicleucelum 260-500 x 10⁶ car-positive viable t zellen - von 260 bis 500 × 10e6 car-positiven lebensfähigen t-zellen - beutel 260 bis 500 × 10e6 car-positiven lebensfähigen t-zellen: idecabtagenum vicleucelum 260-500 x 10⁶ car-positive viable t zellen, natrii chloridum, natrii gluconas, natrii acetas trihydricus, kalii chloridum, magnesii chloridum 4.5-hydricum, aqua ad iniectabile, cryostor cs10, ad praeparationem pro. - abecma ist für die behandlung von erwachsenen patienten mit rezidiviertem und refraktärem multiplem myelom indiziert, die zuvor mindestens drei therapien erhalten haben, inklusive einem immunmodulatorischen wirkstoff, einem proteasom-inhibitor und einem anti-cd38-antikörper, und welche eine progredienz zur letzten therapie gezeigt haben. - transplantat: gentherapieprodukt

Austria - Jerman - AGES (Agentur für Gesundheit und Ernährungssicherheit)

teva b.v. - posaconazol -

Austria - Jerman - AGES (Agentur für Gesundheit und Ernährungssicherheit)

stada arzneimittel gmbh - posaconazol -

Austria - Jerman - AGES (Agentur für Gesundheit und Ernährungssicherheit)

stada arzneimittel gmbh - posaconazol -

Austria - Jerman - AGES (Agentur für Gesundheit und Ernährungssicherheit)

lipomed gmbh - dacarbazin - dacarbazin

Austria - Jerman - AGES (Agentur für Gesundheit und Ernährungssicherheit)

lipomed gmbh - dacarbazin -

Austria - Jerman - AGES (Agentur für Gesundheit und Ernährungssicherheit)

lipomed gmbh - dacarbazin -

Uni Eropa - Jerman - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

alvogen pharma trading europe eood (8188635) - posaconazol - magensaftresistente tablette - 100 mg - posaconazol (29576) 100 milligramm